Skip to main content

Catheter-related Bloodstream Infection (CRBSI) Nos

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

TauroPharm
TauroPharmGermany - Waldbüttelbrunn
1 program
1
TaurolockTMHep100Phase 41 trial
Active Trials
NCT01948245Unknown42Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TauroPharmTaurolockTMHep100

Clinical Trials (1)

Total enrollment: 42 patients across 1 trials

NCT01948245TauroPharmTaurolockTMHep100

Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.

Start: Oct 2013Est. completion: Dec 201642 patients
Phase 4Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.